MSB (ASX) Ann: Mesoblast Type A Meeting with FDA

Originally posted by irenekwshiu: ↑

Below is an answer to “”What’s the difference between clinical trials and registration trials, the latter has not been used before in any announcements, and it is available on appliedclinical trials online .com:

“While clinical trials focus on efficacy—the extent to which medical interventions achieve health improvements under ideal circumstances—registries provide strong evidence for the extent to which medical interventions achieve health improvements in real practice settings.”

It is an answer to Whytee’s comment that it is all about a randomised, controlled trial. No, it is not. Instead, it is about real world evidence, something increasingly leaned upon by the FDA in the last few years in approvals, that will support the adult label extension if and when the potency work is finished. Remember that the BLA is still an application for approval of the children’s aGVHD indication and so this work is still targeted to that BLA. The trial design for the label extension is the extra regulatory step or procedure discussed in the Type A meeting.

It is clear that the last few bullet points in the announcement are the same as what the company discussed in the latest annual results CC and confirmed in the Type A meeting. Whereas the company had likely hoped that the trial design for the label extension would be signed off in the meeting as well, the FDA wanted to see it first finish the final potency work to demonstrate the standardisation of the trial product and the inventory which will go into the trial.

In the fourth last bullet point in the announcement, the company expresses confidence that in doing so, it will be able to provide the link between the trial product and the inventory. Note this is the concept of “similar enough” introduced by Dr. Krause. It’s specifically applicable to and essential for donor stem cell products. We have gone past the proof of efficacy or efficaciousness, and the FDA is focused on the need for the BLA applicant to show that it is going to be able to sell and/or use in future trials a consistent, commercial product. This then lays the foundation for the next step, which is the label extension for not only the adult indication, but other things like IBD and lung ie. ARDS (note not limited to Covid related anymore).

To me, this is progress, not gilding the lily, that represents the last step in the children’s aGVHD BLA approval plus the adult label extension.

Patience is still needed though, panic not so much.

Expand

Note the term I was focused on, being “registration trial”. Registration trials are about real world, as opposed to clinical, evidence.

This company’s Remestemcel product will rely on from now on for label extensions (plural) on real world evidence. It’s gone past the clinic.

This is worth applauding - if the potency work is done to the FDA’s satisfaction. It will no longer be confounding when it happens. The time and money invested in the additional potency assay work in the most difficult years in global healthcare history will hopefully not prove to have been a waste, but rather, lay a solid foundation for a class of therapies.

No.	Vol.	Price($)
1	962	$1.04

No.

Vol.

Price($)

962

$1.04

Price($)	Vol.	No.
94.5¢	3941	1

Price($)

Vol.

No.

94.5¢

3941

No.	Vol.	Price($)
9	162382	0.990
9	73573	0.985
12	170650	0.980
11	128335	0.975
13	267300	0.970

No.

Vol.

Price($)

162382

0.990

73573

0.985

170650

0.980

128335

0.975

267300

0.970

Price($)	Vol.	No.
0.995	47682	2
1.000	51020	9
1.005	81648	8
1.010	76302	8
1.015	37691	2

Price($)

Vol.

No.

0.995

47682

1.000

51020

1.005

81648

1.010

76302

1.015

37691

(20min delay)
Last 99.0¢		Change 0.000(0.00%)		Mkt cap ! $1.130B

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Note the term I was focused on, being “registration trial”....

ASX Market Open: Futures down almost 0.25% on negative data from China

Hotly watched WA1 Resources posts 200Mt niobium resource; largest discovery in over 70 years

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Infini hits "stunning" uranium assays with grades over 1% from soil at Portland Creek

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Note the term I was focused on, being “registration trial”....

Top Stories

ASX Market Open: Futures down almost 0.25% on negative data from China

Hotly watched WA1 Resources posts 200Mt niobium resource; largest discovery in over 70 years

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Infini hits "stunning" uranium assays with grades over 1% from soil at Portland Creek

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News